J.M. del Campo

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

J.M. del Campo, A. Roszak, Mariusz Bidziński et al. · Annals of Oncology · 2009 · 66 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Long-Term Survival in Advanced Ovarian Cancer after Cytoreduction and Chemotherapy Treatment

J.M. del Campo, Enriqueta Felip, Diego Rubio et al. · Gynecologic Oncology · 1994 · 52 citations

Medicine, Gynecology, Oncology +16

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

Andrés Poveda, J.M. del Campo, Isabelle Ray‐Coquard et al. · Annals of Oncology · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +15

Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke

Vicky Chalos, Esmée Venema, Maxim J.H.L. Mulder et al. · JAMA Neurology · 2023 · 40 citations · Full text

Medicine, Neurology, Neurosurgery +17

Update in the management of ovarian and cervical carcinoma

Andrés Poveda, Ramón Salazar, J.M. del Campo et al. · Clinical & Translational Oncology · 2007 · 19 citations

Medicine, Gynecology, Oncology +12